Contraindicated (1)pentobarbital will decrease the level or influence of cariprazine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. CYP3A4 is accountable for the development and elimination of cariprazine's active metabolites.
pentobarbital will minimize the level or impact of lonafarnib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lonafarnib is often a sensitive CYP3A4 substrate. Coadministration with strong or moderate CYP3A4 inducers is contraindicated.
pentobarbital will lower the level or outcome of fosaprepitant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.
This drug may perhaps enhance the metabolism of estradiol when administered concurrently; clients on oral contraceptives have become pregnant when concurrently dealt with with antiepileptic drugs; advise an alternate contraceptive strategy to Gals taking this drug
CYP3A4 inducers may improve the development with the neurotoxic/nephrotoxic ifosfamide metabolite, chloroacetaldehyde. Carefully keep an eye on individuals taking ifosfamide with CYP3A4 inducers for toxicities and consider dose adjustment.
Remark: Barbiturates might increase adverse effects, which include respiratory depression, made by poisonous doses of TCAs. With therapeutic doses of TCAs, barbiturates improve metabolism and reduce blood concentrations of TCAs.
pentobarbital will lessen the level or result of elagolix by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
pentobarbital will minimize the extent or outcome of dasatinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
pentobarbital will minimize the level or result of conjugated estrogens, vaginal by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
Contraindicated (1)pentobarbital will lessen the extent or outcome of naloxegol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Utilization of naloxegol with powerful CYP3A4 inducers is just not advised
pentobarbital will minimize the extent or outcome of fentanyl transdermal by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Observe Intently. Coadministration of fentanyl with CYP3A4 more info inducers may lead into a lower in fentanyl plasma concentrations, deficiency of efficacy or, potentially, growth of a withdrawal syndrome in a very patient who's got made physical dependence to fentanyl.
pentobarbital will reduce the extent or result of buspirone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.
Contraindicated (one)pentobarbital will minimize the extent or effect of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lonafarnib is often a sensitive CYP3A4 substrate. Coadministration with powerful or reasonable CYP3A4 inducers is contraindicated.
pentobarbital will minimize the extent or outcome of sulfamethoxazole by affecting hepatic enzyme CYP2C9/ten metabolism. Minor/Significance Unidentified.